Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

Abstract

The responses observed in the phase I and II clinical trials were significant and of long duration. The partial-responder group included patients who continued to respond from phase I, as well as those who started to respond during the phase II trial.